Corcept Q2 Revenue Jumps 32% on Lifyorli Launch; CEO, CAO Adopt 10b5-1 Plans
CORT has more than doubled off its 52-week low of $28.66.
Summary
Corcept's Q2 revenue surged 32% to $256.1M on the Lifyorli launch, but six-month net income fell to $11.2M due to higher launch costs. The relacorilant NDA for Cushing's was resubmitted with a December 2026 PDUFA date. CEO and other insiders adopted 10b5-1 plans to sell up to 623,606 shares.
Key Events · Earnings and Guidance · CORT
-
Q2 Revenue Beats on Lifyorli Launch
Total revenue of $256.1M, up 32% YoY. Lifyorli contributed $47.6M in its first full quarter; Hypercortisolism Products grew 7% to $208.6M.
-
Profitability Squeezed by Launch Costs
Q2 net income of $43.0M ($0.36 diluted EPS) vs $35.1M a year ago, but six-month net income fell to $11.2M from $55.7M as SG&A nearly doubled to $302.3M for the Lifyorli launch.
-
Relacorilant NDA Resubmitted; December PDUFA
The NDA for relacorilant in Cushing's syndrome was resubmitted June 17, 2026, with a PDUFA target date of December 17, 2026 — a major binary catalyst.
-
CEO, CAO, Director Adopt 10b5-1 Plans
CEO Joseph Belanoff (up to 400,000 shares), CAO Joseph Lyon (120,000), and Director David Mahoney (103,606) adopted Rule 10b5-1 trading plans in May/June 2026.
Analysis · CORT · Life Sciences
Corcept's Q2 results show a strong commercial launch of oncology drug Lifyorli, which contributed $47.6M in its first quarter on the market, driving total revenue to $256.1M — a 32% increase year-over-year. The core Cushing's franchise also grew, with Hypercortisolism Products revenue up 7% to $208.6M. However, the six-month net income dropped sharply to $11.2M from $55.7M a year ago, as SG&A expenses nearly doubled to support the Lifyorli launch. The company holds a robust $544.6M in cash and securities, providing ample runway. On the regulatory front, the relacorilant NDA for Cushing's syndrome was resubmitted in June with a December 17, 2026 PDUFA date — a critical catalyst. The legal landscape remains challenging: the Federal Circuit denied rehearing of the Teva patent loss, cementing generic Korlym competition, and multiple litigations (securities class action, antitrust, qui tam) are ongoing. Separately, the CEO, CAO, and a director adopted 10b5-1 trading plans covering up to 623,606 shares, which could create overhang. The stock is trading near its 52-week high, reflecting optimism around Lifyorli and the relacorilant resubmission, but the insider selling plans and legal overhangs warrant attention.
At the time of this filing, CORT was trading at $112.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10B. The 52-week trading range was $28.66 to $97.63. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.